Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Application

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 12, 2008, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Start Printed Page 16720

DrugSchedule
Cathinone (1235)I
Methcathinone (1237)I
Aminorex (1585)I
Alpha-ethyltryptamine (7249)I
Lysergic acid diethylamide (7315)I
Tetrahydrocannabinols (7370)I
4-Bromo-2,5-dimethoxy-amphetamine (7391)I
4-Bromo-2,5-dimethoxyphenethylamine (7392)I
2,5-Dimethoxyamphetamine (7396)I
3,4-Methylenedioxyamphetamine (7400)I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)I
3,4-Methylenedioxy-N-ethylamphetamine (7404)I
3,4-Methylenedioxymethamphetamine (MDMA) (7405)I
Psilocybin (7437)I
5-Methoxy-N,N-diisopropyltryptamine (7439)I
1-[1-(2-Thienyl) cyclohexyl] piperidine (TCP) (7470)I
1-Benzylpiperazine (BZP) (7493)I
Heroin (9200)I
Normorphine (9313)I
Amphetamine (1100)II
Methamphetamine (1105)II
Nabilone (7379)II
1-Phenylcyclohexylamine (7460)II
Phencyclidine (7471)II
Cocaine (9041)II
Codeine (9050)II
Diprenorphine (9058)II
Ecgonine (9180)II
Levomethorphan (9210)II
Levorphanol (9220)II
Meperidine (9230)II
Metazocine (9240)II
Methadone (9250)II
Morphine (9300)II
Thebaine (9333)II
Levo-alphacetylmethadol (9648)II
Carfentanil (9743)II
Fentanyl (9801)II

The company plans to manufacture reference standards.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 27, 2008.

Start Signature

Dated: March 19, 2008.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. E8-6364 Filed 3-27-08; 8:45 am]

BILLING CODE 4410-09-P